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Abstract
Objective The objective of this study was to investigate out-
comes for patients with brainstem metastases treated with ste-
reotactic radiosurgery (SRS).
Methods Patients with brainstem metastases treated with SRS
between April 2006 and June 2012 were identified from a
prospective database. Patient and treatment-related factors
were recorded. Kaplan-Meier analysis was used to calculate
survival and freedom from local and distant brain progression.
Univariate and multivariate Cox regression was used to iden-
tify factors important for overall survival.
Results In total, 44 patients received SRS for 48 brainstem
metastases of whom 33 (75 %) also received whole brain
radiotherapy (WBRT): 23 patients (52 %) WBRT prior to
SRS, 6 (13.6 %) WBRT concurrently with SRS and 4
(9.0 %) WBRT after SRS. Eight patients received a second
course ofWBRTat further progression. Median target volume
was 1.33 cc (range 0.04–12.17) and median prescribed mar-
ginal dose was 15 Gy (range 10–22). There were four cases of
local failure, and 6-month and 1-year freedom from local fail-
ure was 84.6 and 76.9 %, respectively. Median overall surviv-
al (OS) was 5.4 months. There were four cases of
radionecrosis, 2 (4.8 %) of which were symptomatic. The
absence of external beam brain radiotherapy (predominantly
WBRT) showed a trend towards improved OS on univariate
analysis. Neither local nor distant brain failure significantly
impacted OS.
Conclusion This retrospective series of patients treated with
SRS for brainstem metastases, largely in combination with at
least one course of WBRT, demonstrates that this approach is
safe and results in good local control. In this cohort, no vari-
ables significantly impacted OS, including intracranial
control.
Keywords Stereotactic radiosurgery . Brainstemmetastases .
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Introduction
Between 20 and 40 % of patients with cancer develop brain
metastases of which 2–5% arise in the brainstem [1–5].While
brainstem metastases represent a small proportion of brain
metastases overall, these lesions are challenging in terms of
management, and prognosis is traditionally poor. Given the
critical functions performed by the brainstem, surgery is not
typically utilised, and the preferred treatment is with radiation,
either with conventionally fractionated external beam radio-
therapy or stereotactic radiosurgery (SRS).
Radiosurgery is an established treatment modality for brain
metastases, commonly offered when the metastases are limit-
ed in number and size (generally <3 cm in diameter) [6]. The
highly conformal nature of SRS treatment allows a much
higher dose to be delivered to the tumour than can be achieved
with conventionally fractionated radiotherapy, without exces-
sive damage to the surrounding normal tissues.
Since the brainstem is considered an eloquent area, where
salvage surgical resection in the event of brainstem
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radionecrosis is not easily achieved, there have been concerns
about the safety of SRS in this location. Given this, and the
fact that brainstemmetastases are relatively infrequent, the use
of SRS in the brainstem is relatively under-represented in the
literature. Here, we present the clinical outcomes for 44 pa-
tients with 48 brainstem metastases treated with SRS with and
without whole brain radiotherapy along with investigation of




Following approval by the institutional research ethics board
for the period April 2006 to June 2012, patients who received
SRS at University Health Network (Princess Margaret Cancer
Centre and Toronto Western Hospital) for brainstem metasta-
ses during the above time period were identified from a pro-
spective brain metastases database. The following details were
recorded: age, gender, primary tumour histology, number of
brainstem lesions, brainstem location, presence of additional
non-brainstem brain metastases at time of brainstem SRS,
extra-cranial disease control at time of brainstem SRS, use
of additional radiotherapy and dose, site and timing of addi-
tional brain radiotherapy.
Stereotactic radiosurgery
All patients were treated using the Gamma Knife® 4C or
Perfexion™ radiosurgery unit (Elekta AB, Stockholm,
Sweden). Patients were immobilised using a Leskell stereo-
tactic frame. Using the GammaPlan® system (Elekta AB,
Stockholm, Sweden), patient MR (gadolinium-enhanced T1-
weighted and T2-weighted) and CT images were imported for
target and organ-at-risk delineation, and radiosurgery plans
were generated. All patients received single fraction SRS.
The dose prescriptions were based on volume and generally
followed the RTOG guidelines, while limiting dose to the
surrounding brainstem to try to keep the maximum dose to
1mm3 brainstem less than 15 Gy. It was aimed to keep the
conformality index less than 2. The following dosimetric pa-
rameters were recorded: target volume, largest extent of target,
conformality index, gradient index, minimum target dose,
maximum target dose, mean target dose, and prescription
isodose.
Patient follow-up
All patients were reviewed prior to SRS in a dedicated multi-
disciplinary brain metastases clinic. Following SRS, all pa-
tients were followed up in the same clinic at 3-month intervals,
with serial brain MRI and neurological assessment. Changes
in target lesions were defined according to RECIST criteria
[7], as a number of these brainstemmetastases did not all meet
the minimum diameter requirement of 10 mm described in the
Response Assessment in Neuro-Oncology criteria for brain
metastases [8].
Statistics
All statistical analysis was completed using SPSS version 21
(IBM, USA), and p < 0.05 was considered statistically signif-
icant. The Kaplan-Meier method was used to calculate surviv-
al outcomes. Overall survival was defined as the date of
Gamma Knife treatment to date of death or censored at last
follow-up. For overall survival and distant brain failure, cal-
culations were on a per patient basis (i.e. patients with more
than one brainstem lesion were only considered once in the
analysis), and where patients had brainstem lesions treated
sequentially, overall survival was considered from the date
of the first brainstem radiosurgery treatment. Local failure
was defined on an individual lesion basis as the date of
Gamma Knife treatment to the date of first reported radiolog-
ical progression. Lesions that progressed on imaging and/or
caused new neurologic symptoms but which resolved without
any further anti-cancer treatment were considered
radionecrosis rather than local progression. Distant brain fail-
ure was defined as the development of new metastases in the
brain but not within the brainstem.
Univariate and multivariable Cox regression were used to
investigate factors predictive of overall survival. For univari-
ate analysis, patient age, gender, primary tumour histology
(breast, non-small cell lung vs. other), the use of additional
brain radiotherapy, the presence of synchronous non-
brainstem brain metastases at the time of brainstem SRS,
extra-cranial disease control, local failure and distant brain
failure were evaluated. Any covariates with a p value of 0.1
or less were intended for inclusion in the multivariable model
for overall survival. Factors potentially predictive of local
control or radionecrosis were not investigated in a univariate




In total, 44 patients received SRS for 48 brainstem lesions,
including 3 patients in whom two brainstem lesions were
treated synchronously and one patient who received two se-
quential SRS treatments to the same brainstem metastasis.
Baseline characteristics are shown in Table 1. Median
follow-up was 16.1 months (range 0–54.0). Median age at
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SRS was 58 years (range 32–76) and 36 % of patients were
male (n = 16). All patients had KPS > 60 at the time of
brainstem SRS. Themost frequent primary tumour histologies
were non-small cell lung cancer (n = 14, 32 %) and breast
cancer (n = 12, 27 %). Brainstem metastases represented the
only intra-cranial metastasis in 17 patients (39 %), while 11
patients (25 %) had one other brain lesion at the time of
brainstem SRS, and the remainder had two or more additional
lesions (up to a maximum of 9 non-brainstem brain metasta-
ses). The majority (n = 33, 75 %) of patients received whole
brain radiotherapy (WBRT) during their course of care: 23
patients (52 %) had received WBRT prior to SRS to the
brainstem metastases, 6 patients (13.6 %) received WBRT
concurrently with brainstem SRS (defined as within 4 weeks
of SRS) and 4 patients (9.0 %) received WBRT after SRS. A
further two patients received base of skull radiotherapy prior
to brainstem SRS and one additional patient received radio-
therapy for a temporal bone lesion prior to brainstem SRS. In
8 patients, a second course of WBRT was also delivered at
further progression, and in 1 patient, who received base of
skull radiotherapy prior to brainstem SRS, WBRT was deliv-
ered at further progression.
Dosimetry
Dosimetric factors are summarised in Table 2. The most com-
monly prescribed marginal dose was 15 Gy (n = 38 lesions,
79.2 %), most often prescribed to the 50 % isodose (median
prescription isodose: 50 %, range 39–80 %), resulting in a
median mean dose of 20.8 Gy (range 13.9–35.0). The median
brainstem metastasis volume was 1.33 cc (range 0.04–
12.17 cc). Plans were highly conformal with steep dose gra-
dients (Table 2), thus limiting the dose to the surrounding
normal tissues. Of the 33 patients who received WBRT, 18
(54.5 %) received 20 Gy in 5 fractions, 14 (31.8 %) received
30 Gy in 10 fractions and 1 (2.3 %) received 25 Gy in 10
fractions. Both of the patients who received base of skull
radiotherapy prior to SRS received 20 Gy in 5 fractions and
the one patient who had received radiotherapy for a temporal
bone lesion received 55 Gy in 50 fractions in a BID schedule
resulting in a maximum brainstem dose of 22 Gy. Of the 8
patients who received 2 courses of WBRT, patients largely
received 20 Gy in 5 fractions for their first course of WBRT,
with just 2 patients who received 30Gy in 10 fractions. Half of
patients received 25 Gy in 10 fractions for their second course
of WBRT, although 20 Gy in 10 fractions and 15 Gy in 5
fractions were also delivered as the second course. The full
summary is provided in Online Resource 1. One patient who
had received skull base radiotherapy, 20 Gy in 5 fractions,
prior to brainstem SRS also went on to receive WBRT follow-
ing brainstem SRS at a dose of 25 Gy in 10 fractions.
Survival and brain response
Median overall survival was 23.6 weeks (95 % CI: 16.2 to
31.0 weeks) with 1- and 2-year overall survival of 33.4 and
15.6 %, respectively (Fig. 1a). There were no deaths within
30 days of brainstem SRS.
Table 1 Baseline characteristics (no. patients: 44, no. lesions: 48)
Factor n %


















Number of brainstem lesions
1 40 90.9
2 treated synchronously 3 6.8
2 treated sequentially 1 2.3








WBRT prior to SRS 23 52.3
Other brain RT prior to SRSa 3 6.8
WBRT concurrent with SRS 6 13.6
WBRT after SRS 4 9.1
Re-WBRT after SRS 8 18.2




SRS stereotactic radiosurgery, WBRTwhole brain radiotherapy
a Two patients have base of skull radiotherapy and one had IMRT for a
temporal bone lesion
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Overall, 27 brainstem metastases (in 25 patients) were
evaluable on follow-up MRI imaging. Response was un-
known for the remaining 21 lesions (19 patients), due to death
prior to the 3-month post-SRS scan (n = 9) or loss to imaging
follow-up. Of the 27 lesions with imaging follow-up, there
were 2 complete responses, 12 partial responses and 9 cases
of stable disease. Local failure was recorded on 4 occasions in
3 patients, including the 1 patient who was treated with sal-
vage radiosurgery to the same brainstem metastasis. The 6-
month, 1- and 2-year freedom from local failure was 84.6,
76.9 and 61.5 %, respectively (Fig. 1b). Of the 3 patients
who developed local failure, two had a diagnosis of non-
small cell lung cancer and one had breast cancer. All 3 patients
had received WBRT prior to brainstem SRS. In all 4 cases of
local failure, the metastases were relatively small (volumes:
0.4–3.57 cc, maximum diameters: 10.5–21 mm). In all 3 pa-
tients with local failure, the marginal prescription dose was
15 Gy for the first brainstem SRS treatment. For the one pa-
tient (with a diagnosis of breast cancer) who received a second
SRS treatment for local progression of the brainstem metasta-
sis, a marginal dose of 12 Gy was prescribed for re-treatment.
Following the brainstem SRS retreatment, there was radiolog-
ical evidence of progression of the retreated brainstem lesion.
This was accompanied by progression of additional non-
brainstem brain metastases. Progression of all intra-cranial
lesions continued on serial imaging, and so appearances were
in keeping with disease progression and not brainstem
radionecrosis. Thus, despite two SRS treatments to the
same area (and previous WBRT), this patient did not
develop radionecrosis or any other signif icant
treatment-related toxicity.
Distant brain progression was reported in 14 patients of
whom 8 (57.1%) had received priorWBRT. Of the 29 patients
who received WBRT prior to or concurrent with brainstem
SRS, 8 (27.6 %) developed distant brain progression com-
pared to 6 of the 12 patients (50 %) who received SRS alone.
Within the whole group, median time to distant brain progres-
sion was 56.1 weeks with 6-month, 1- and 2-year freedom
from distant brain progression of 54.8, 54.8 and 25.1 %, re-
spectively (Fig. 1c).
Treatment-related toxicity
Radionecrosis was observed in 4 patients (9 %), 2 of whom
were symptomatic (4.5 % of all patients). Of the two symp-
tomatic patients, one developed quadriparesis 6 months after
SRS and improved clinically and on imaging with dexameth-
asone. The other symptomatic patient developed right leg
pain, dizziness and speech difficulties 7 months after SRS.
The patient had partial improvement with dexamethasone
and subsequently received hyperbaric oxygen, which
stabilised symptoms and improved the radiologically evident
edema. The two asymptomatic patients developed
radionecrosis 6 and 8 months following SRS. All 4 patients
were prescribed marginal prescription doses of 15 Gy to rela-
tively small brainstem lesions (target volumes: 1.26 cc to
3.18 cc, maximum dimensions: 19.0 to 22.4 mm) and all
had received prior whole brain radiotherapy (20 Gy in 5 frac-
tions in 2 patients and 30 Gy in 10 fractions in 2 patients).
Other than these cases of radionecrosis, there were no other
grade 3 or greater toxicities.
Factors predictive of survival
On univariate analysis, no factors were identified that had a
statistically significant impact on overall survival (Table 3).
There was a trend towards better overall survival in patients
who did not receive external beam brain radiotherapy
(p = 0.078), which included WBRT (n = 33), base of skull
(n = 2) or temporal bone (n = 1) radiotherapy (Fig. 2). Neither
local failure, nor distant brain failure, had a statistically signif-
icant impact on overall survival. As above, given the small
sample size and low number of events, statistical exploration
for factors predictive of local control or toxicity was not
performed.
Discussion
Despite the precision and dose conformality of radiosurgery,
there have been concerns about the safety of using SRS for the
treatment of brainstem metastases. Our retrospective study
supports that SRS for brainstem metastases results in good
local control (76.9 % at 1 year) and is well tolerated by the
Table 2 Dosimetric parameters
Parameter Median Range
Target volume (cc) 1.33 0.04–12.17
Largest extent of target (mm) 16.95 4.70–37.00
Prescribed dose (Gy) n %
15 Gy 38 79.2
12 Gya 6 12.5
10 Gy 1 2.1
14 Gy 1 2.1
18 Gy 1 2.1
22 Gy 1 2.1
Prescription isodose (%) 50 39–80
Conformality index 1.25 1.04–2.85
Gradient index 2.90 2.29–4.44
Target minimum dose (Gy) 12.90 7.94–19.56
Target maximum dose (Gy) 29.94 18.76–48.98
Target mean dose (Gy) 20.83 13.89–34.96
a This dose was used for the one case of SRS re-treatment of a brainstem
metastasis
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Fig. 1 a Overall survival. b
Freedom from local failure. c
Freedom from distant brain
failure
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majority of patients with symptomatic radionecrosis in only 2
patients (4.5 %). This is one of the largest series describing
outcomes following WBRT in combination with brainstem
SRS (n = 33), and to our knowledge, this is the largest reported
experience of patients treated with a second course of WBRT
at progression after brainstem SRS (n = 8). Our experience,
along with 2 other studies involving a total of only 6 patients,
demonstrates the safe delivery of 2 courses of WBRT with
SRS to the brainstem without significant toxicity [9, 10].
In our review of the literature, a further 20 studies have
specifically examined SRS for brainstem metastases using
Gamma Knife or linear accelerator-based SRS (Table 4),
[11–23, 10, 24, 9, 25–28]. Although patient numbers tend to
be small, collectively, these studies report outcomes for over
1000 patients and over 1100 brainstemmetastases treated with
SRS. Based on these publications, we can generally conclude
that high rates of local control can be achieved with infrequent
serious toxicity in this patient population with relatively short
overall survival. Median overall survival was 5.4 months in
this current study, towards the lower end of that reported in
other series with median survival ranging from 4.9 to
12 months (Table 4), perhaps reflecting the fact that most of
the patients (75 %) in this series received brainstem SRS as a
salvage treatment following previousWBRT, rather than as an
upfront treatment option. It has been observed that brainstem
metastases, more than other intra-cranial locations, have a
negative impact on overall survival [29, 30], with median
survivals of 4.4 and 6.5 months with and without brainstem
metastases reported in one matched analysis [30]. Although
the brainstem location appears to impact overall survival, nei-
ther local nor distant brain failure significantly impacted over-
all survival in our study.
There have been mixed reports about the impact of mar-
ginal dose on outcomes including overall survival and local
Table 3 Univariate analysis for
overall survival (hazard ratio and
95 % confidence interval only









Additional external beam brain radiotherapy (received vs. not
received)a
0.078 3.804 0.861–16.806
Synchronous non-brainstem brain metastases at time of brainstem
SRS (present vs. absent)
0.250
Histology of primary lesion 0.365
Extra-cranial disease control at time of brainstem SRS 0.609
Local brain failure (yes vs. no) 0.187
Distant brain failure (yes vs. no) 0.592
a Factor entered into multivariate model
Fig. 2 Patients receiving SRS for
brainstem metastases, with or
without additional external beam
brain radiotherapy (blue line: no
other brain radiotherapy, green
line: other brain radiotherapy;
p = 0.078)
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control. Lorenzoni et al. identified that doses above 18 Gy
predicted improved overall survival, and Trifiletti et al. and
Kased et al. both demonstrated that doses of 16 Gy and above
resulted in improved local control [16, 25, 28]. Other studies
did not find marginal dose as an important predictor for local
control or overall survival in patients treated with SRS for
brainstemmetastases [18, 19, 21, 24, 26]. Despite the majority
of our patients receiving a lower marginal prescription dose of
15 Gy compared with other studies, local control was 78.6 %
at 1 year in our series compared with at least 74 to 88 % in
other series. (Table 4) and our overall survival was compara-
ble to other studies. Relative to other studies that reported
WBRT doses up to 45 Gy combined with SRS to the
brainstem, the WBRT doses employed in our study were low-
er and hypofractionated [11, 12, 17–19, 22, 23], but outcomes
were similar to published series. The impact of WBRT dose
on local control and toxicity when used in conjunction with
brainstem SRS has not been investigated or reported
previously.
In this current study, brainstem SRS was well tolerated by
most patients with 4 cases of radionecrosis as the only
treatment-related toxicities, of which only 2 patients were
symptomatic. In existing studies, serious toxicities have also
been uncommon, consistently involving less than 10 % of
patients (Table 4). Kilburn et al. observed that larger treatment
volumes were predictive of toxicity in a series of 44 patients in
whom 4 patients developed toxicity (one grade 2, three grade
3), including 2 patients who developed symptomatic
radionecrosis (4.4 %) [24]. Our rate of symptomatic
radionecrosis was similar at 4.5 %, but the target volumes in
the cases that developed radionecrosis were small.
Due to the retrospective nature of this study, there are lim-
itations with the data presented. Firstly, a relatively high pro-
portion of patients were not evaluable for imaging response to
brainstem SRS with about half of patients, who died prior to
imaging and the other half who did not complete their 3-
month post-treatment MRI. The large number lost to follow-
up may reflect a combination of factors including the clinical
state of these patients with advanced disease who may have
been too unwell to attend for further imaging and the long
distances patients have needed to travel for follow-up at this
large tertiary cancer centre that received referrals from both
nearby and remote regions. In addition, due to the retrospec-
tive nature of this study, we had incomplete data regarding the
details of the presenting symptoms, consistent evaluation in
any change of symptoms or dexamethasone use. Therefore,
these variables were not included in any statistical analyses.
Despite the large collective number of patients now report-
ed to have received SRS for brainstem metastases, as with this
current series, individual studies tend to contain small num-
bers of patients, limiting the ability to identify factors predic-
tive of local control or overall survival [19, 24, 26]. Even
where statistically significant observations are made, one
should exercise caution in the interpretation due to the small
sample sizes relative to the number of predictive variables
investigated. In this current study, trends were observed to-
wards improved overall survival with the absence of addition-
al fractionated brain radiotherapy and the absence of synchro-
nous non-brainstem brain metastases at the time of SRS. In
terms of the use of whole brain radiotherapy, Lorenzoni et al.
and Jung et al. similarly found that the absence of whole brain
radiotherapy was a significant predictor of improved survival
[23, 25]. In both of these studies, like our study, the majority of
patients received SRS as salvage treatment following initial
whole brain radiotherapy. As such, these patients were likely
later in their course of disease and therefore had an expected
shorter survival following SRS than patients who had not
received prior brain radiotherapy.
Conclusion
This retrospective series of patients treated with SRS for
brainstem metastases, largely in combination with at least
one course of whole brain radiotherapy, demonstrates that this
treatment approach is safe and results in good local control.
Distant brain failure was lower in patients who received whole
brain radiotherapy as part of initial brain metastasis treatment,
as demonstrated in prior studies. In this cohort, no variables
significantly impacted overall survival, including intracranial
control.
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